Rajesh Krishnan
Chief Tech/Sci/R&D Officer chez ONCTERNAL THERAPEUTICS, INC.
Fortune : 19 809 $ au 31/03/2024
Profil
Rajesh Krishnan is currently the Chief Technology Officer at Oncternal Therapeutics, Inc. Prior to his current position, he held the role of Head-Biologics Drug Substance Process Development at Gilead Sciences, Inc. from 2012 to 2017.
He also served as the VP-Process Development & Manufacturing Sciences at Dynavax Technologies Corp.
from 2018 to 2019.
Dr. Krishnan completed his undergraduate degree at Princeton University and holds graduate and doctorate degrees from the University of California, Davis.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 14/02/2024 | 2 201 ( 0,07% ) | 19 809 $ | 31/03/2024 |
Postes actifs de Rajesh Krishnan
| Sociétés | Poste | Début |
|---|---|---|
| ONCTERNAL THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | - |
Anciens postes connus de Rajesh Krishnan
| Sociétés | Poste | Fin |
|---|---|---|
| DYNAVAX TECHNOLOGIES CORPORATION | Corporate Officer/Principal | 01/01/2019 |
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 01/01/2017 |
Formation de Rajesh Krishnan
| Princeton University | Undergraduate Degree |
| University of California, Davis | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| DYNAVAX TECHNOLOGIES CORPORATION | Health Technology |
| ONCTERNAL THERAPEUTICS, INC. | Health Technology |
